Natural Product (NP) Details

General Information of the NP (ID: NP0165)
Name
Voglibose
Synonyms
voglibose; 83480-29-9; Glustat; Basen; AO-128; UNII-S77P977AG8; A-71100; Voglibosa; CHEMBL476960; (1S,2S,3R,4S,5S)-5-((1,3-dihydroxypropan-2-yl)amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol; S77P977AG8; AO 128; DSSTox_CID_1442; DSSTox_RID_76161; DSSTox_GSID_21442; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol; (1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; Voglibosum; 3,4-Dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol; Basen OD; 3,4-DIDEOXY-4-[[2-HYDROXY-1-(HYDROXYMETHYL)ETHYL]AMINO]-2-C-(HYDROXYMETHYL)-D-EPINOSITOL; CAS-83480-29-9; Basen (TN); Voglibose [USAN:INN]; Voglibosum [INN-Latin]; Voglibosa [INN-Spanish]; CCRIS 4540; Voglibose/; NCGC00164595-01; 3,4-Dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epi-inositol; VOG; SCHEMBL5882; A 71100; MLS003882582; Voglibose (JP17/USAN/INN); DTXSID2021442; CHEBI:32300; AOB5593; BCPP000020; HMS3414A17; HMS3678A17; Voglibose, >=97.0% (TLC); HY-B0025; ZINC3788703; Tox21_112220; ABP000769; BDBM50263044; s4101; AKOS015950839; Tox21_112220_1; CCG-267119; DB04878; NCGC00164595-02; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; SMR002530327; D01665; AB01566929_01; 480V299; SR-01000883931; Q-101310; Q7939403; SR-01000883931-1; BRD-K66850609-001-01-7; BRD-K66850609-001-07-4
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Acute diabete complication [ICD-11: 5A2Y] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -6.198
 
MDCK Permeability
 -4.123
 
PAMPA
 +++
 
HIA
 +++
 
Distribution
VDss
 -0.509
 
PPB
 24.1%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - - -
 
Excretion
CLplasma
 2.249
 
T1/2
 2.237
Toxicity
DILI
 - - -
 
Rat Oral Acute Toxicity
 - - -
 
FDAMDD
 - - -
 
Respiratory
 - - -
 
Human Hepatotoxicity
 +
 
Ototoxicity
 +++
 
Drug-induced Nephrotoxicity
 ++
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 - -
 
Genotoxicity
 - - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C10H21NO7
PubChem CID
444020
Canonical SMILES
C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO
InChI
1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
InChIKey
FZNCGRZWXLXZSZ-CIQUZCHMSA-N
CAS Number
CAS 83480-29-9
ChEBI ID
CHEBI:32300
TTD Drug ID
D04ZTY
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Alogliptin      Type 2 diabetes mellitus     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Alogliptin (0.03%) and voglibose (0.001%) alone or in combination were administered in the diet to prediabetic db/db mice.
                    Experimental
                    Result(s)		 Chronic treatment with alogliptin in combination with voglibose concurrently increased active GLP-1 circulation, increased insulin secretion, decreased glucagon secretion, prevented the onset of the disease, and preserved pancreatic beta-cells and islet structure in prediabetic db/db mice.
Target and Pathway
Target(s) Intestinal maltase-glucoamylase (MGAM)  Molecule Info  [3]
KEGG Pathway Galactose metabolism Click to Show/Hide
2 Starch and sucrose metabolism
3 Metabolic pathways
4 Carbohydrate digestion and absorption
Pathwhiz Pathway Starch and Sucrose Metabolism Click to Show/Hide
WikiPathways Metabolism of carbohydrates Click to Show/Hide
References
Reference 1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Reference 2 Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab. 2010 Mar;12(3):224-33.
Reference 3 Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
 Download Picture         KEGG Link